Skip to main content

Table 8 (A) Quality of life of metastatic gastric cancer patients, (B) Median difference before–after of quality of Life

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

  Mean
(before)
Std.
deviation
Std.
error
P-value Mean
(after)
Std.
deviation
Std.
error
P-value
(A) Quality of life in patients with metastatic gastric cancer
Global quality
(BCc1 nanomedicine)
48.88 13.614 2.779 0.118 45.63 11.009 2.247 0.200
Global quality
(Placebo)
47.16 13.280 3.047 0.200 51.58 12.384 2.841 0.200
  Mean* Std. deviation Std. error mean P-value
(B) Median difference (beforeafter) of quality of life
Quality of BCc1 (before–after) 3.250 8.975 1.832 0.089
Quality of Placebo (before–after) − 4.421 6.947 1.594 0.013
  1. * Higher score show better global quality of life